Phase I study of ontuxizumab, a humanized monoclonal antibody (mAb) recognizing endosialin in Japanese patients (pts) with hepatocellular carcinoma (HCC).

被引：0
作者：
Ikeda, Masafumi
Aramaki, Takeshi
Inaba, Yoshitaka
Nakai, Kenya
Doi, Toshihiko
Okusaka, Takuji
机构：
[1] Natl Canc Ctr Hosp East, Chiba, Japan
[2] Shizuoka Canc Ctr, Shizuoka, Japan
[3] Aichi Canc Ctr Hosp, Dept Intervent & Diagnost Radiol, Nagoya, Aichi 464, Japan
[4] Eisai & Co Ltd, Tokyo, Japan
[5] Natl Canc Ctr, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.2521
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2521
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort in a phase I study
    Pishvaian, M. J.
    Weiss, G. J.
    Falchook, G. S.
    Yee, N.
    Gil-Martin, M.
    Shahda, S.
    Moreno, V.
    Brana, I.
    Crittenden, M.
    Formenti, S.
    Al-Rajabi, R.
    Papadopoulos, K. P.
    Stankevich, E.
    Feng, M.
    Li, J.
    Mathias, M.
    Kroog, G.
    Lowy, I.
    Fury, M. G.
    ANNALS OF ONCOLOGY, 2018, 29
  • [22] A phase I radioimmunolocalization trial of humanized monoclonal antibody huA33 in patients with gastric carcinoma
    Sakamoto, Junichi
    Oriuchi, Noboru
    Mochiki, Erito
    Asao, Takayuki
    Scott, Andrew M.
    Hoffman, Eric W.
    Jungbluth, Achim A.
    Matsui, Takanori
    Lee, F. T.
    Papenfuss, Anthony
    Kuwano, Hiroyuki
    Takahashi, Toshitada
    Endo, Keigo
    Old, Lloyd J.
    CANCER SCIENCE, 2006, 97 (11) : 1248 - 1254
  • [23] A phase I study of ganetespib in advanced hepatocellular carcinoma (HCC)
    Goyal, Lipika
    Wadlow, Raymond Couric
    Blaszkowsky, Lawrence Scott
    Wolpin, Brian M.
    Vasudev, Eamala
    Sheehan, Susan
    Knowles, Michelle
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [24] Randomized, phase I, and pharmacokinetic (PK) study of RAD001, an mTOR inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Chen, L.
    Shiah, H. S.
    Chen, C. Y.
    Lin, Y. J.
    Lin, P. W.
    Su, W. C.
    Chang, J. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [25] Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).
    Finn, R. S.
    Poon, R. T. P.
    Yau, T.
    Klumpen, H.
    Chen, L.
    Kang, Y.
    Kim, T.
    Gomez-Martin, C.
    Rodriguez-Lope, C.
    Kunz, T.
    Paquet, T.
    Asubonteng, K.
    Winkler, R. E.
    Anak, O.
    Sellami, D. B.
    Bruix, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [26] Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort (EC) in a phase I study
    He, A. R.
    Weiss, G. J.
    Falchook, G.
    Yee, N. S.
    Gil-Martin, M.
    Shahda, S.
    Moreno, V.
    Brana, I.
    Crittenden, M.
    Formenti, S.
    Al-Rajabi, R.
    Papadopoulos, K. P.
    Pishvaian, M. J.
    Stankevich, E.
    Feng, M.
    Li, J.
    Mathias, M.
    Kroog, G.
    Lowy, I.
    Fury, M. G.
    ANNALS OF ONCOLOGY, 2018, 29
  • [27] Preliminary results of a phase 1A/1B study of BGB-A317, an anti-PD1 monoclonal antibody (mAb), in patients with advanced hepatocellular carcinoma (HCC)
    Yen Chia-Jui
    Benjamin, Markman
    Chao Yee
    Andrew, Hill
    Kang Jinyu
    Wang Lai
    Li Kang
    Qi Qinzhou
    Wu Zhong
    Gan Hui
    ANNALS OF ONCOLOGY, 2017, 28
  • [28] Phase I/II study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I results
    Mitsunaga, Shuichi
    Ikeda, Masafumi
    Ueno, Hideki
    Nakachi, Kohei
    Morizane, Chigusa
    Kondo, Shunsuke
    Shimizu, Satoshi
    Kojima, Yasushi
    Suzuki, Takuya
    Tamai, Toshiyuki
    O'Brien, James P.
    Okusaka, Takuji
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [29] Phase Ib/II study of sorafenib (SOR) and pembrolizumab (PEM) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Iyer, Renuka
    Sonti, Sahithi
    Mahalingam, Devalingam
    Mukherjee, Sarbajit
    Chakraborty, Sayan
    Attwood, Kristopher
    George, Anthony
    Maguire, Orla
    Minderman, Hans
    Fountzilas, Christos
    CANCER RESEARCH, 2024, 84 (07)
  • [30] A phase II study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Zhu, A. X.
    Finn, R. S.
    Mulcahy, M. F.
    Gurtler, J. S.
    Sun, W.
    Schwartz, J. D.
    Rojas, P.
    Dontabhaktuni, A.
    Youssoufian, H.
    Stuart, K. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345